Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis

Nutrition and Cancer

Volumn 60, Issue SUPPL. 1, 2008, Pages 30-35

  Ignatenko, Natalia A ^a,b   Besselsen, David G ^b,c   Stringer, David E ^b   Blohm Mangone, Karen A ^b   Cui, Haiyan ^b   Gerner, Eugene W ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; EFLORNITHINE; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; COLON POLYPOSIS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; MALE; MONOTHERAPY; MOUSE; NONHUMAN;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANIMALS; BIOGENIC POLYAMINES; CHEMOPREVENTION; EFLORNITHINE; FEMALE; GENES, APC; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; MALE; MICE; MICE, INBRED C57BL; PYRAZOLES; SULFONAMIDES; SULINDAC;

MURINAE; MUS;

EID: 55949129367     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802401317     Document Type: Conference Paper

References (28)

1. Fodde R: The APC gene in colorectal cancer. Eur J Cancer 38, 867-371, 2002.
2. Jass JR: Familial colorectal cancer: pathology andmolecular characteristics. Lancet Oncol 1, 220-226, 2000.
3. Cetta F and Dhamo A: Inherited multitumoral syndromes including colorectal carcinoma. Surg Oncol 16(1 Suppl), S17-S23, 2007.
4. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342, 1946-1952, 2000.
5. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, et al.: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346, 1054-1059, 2002.
6. Gill S and Sinicrope FA: Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Sem Oncol 32, 24-34, 2005.
7. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, et al.: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256, 668-670, 1992.
8. Moser AR, Pitot HC, and Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322-324, 1990.
9. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, et al.: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60, 1864-1870, 2000.
10. Zell JA, Ignatenko NA, Yerushalmi HF, Ziogas A, Besselsen DG, et al.: Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 120, 459-468, 2007.
11. Meyskens FLJ, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, et al.: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo controlled, double-blind trial. Cancer Prev Res 1, 32-38, 2008.
12. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al.: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348, 891-899, 2003.
13. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355, 885-895, 2006.
14. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355, 873-884, 2006.
15. Babbar N, Ignatenko NA, Casero RA Jr, and Gerner EW: Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 278, 47762-47775, 2003.
16. Ignatenko NA, Besselsen DG, Roy UK, Stringer DE, Blohm-Mangone KA, et al.: Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutr Cancer 56, 172-181, 2006.
17. Gerner EW and Meyskens FL Jr.: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4, 781-792, 2004.
18. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, et al.: Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75, 631-639, 1993.
19. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, et al.: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20, 1709-1713, 1999.
20. Zell JA, Yerushalmi HF, Ignatenko NA, Besselsen DE, Ziogas A, et al.: Non-steroidal anti-inflammatory drugs and arginine intake in colorectal tumorigenesis and survival. Int J Cancer 120, 459-468, 2007.
21. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, et al.: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55, 1464-1472, 1995.
22. Jacoby RF, Seibert K, Cole CE, Kelloff G, and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60, 5040-5044, 2000.
23. Saukkonen K, Tomasetto C, Narko K, Rio MC, and Ristimaki A: Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res 63, 3032-3036, 2003.
24. Seiler N and Knodgen B: High-performance liquid chromatography procedure for the simultaneous determination of the natural polyamines and their monoacetylderivatives. J Chromatog 221, 227-238, 1980.
25. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, et al.: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762-777, 2003.
26. Arber N and Levin B: Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology 134, 1224-1237, 2008.
27. Lance P: Chemoprevention for colorectal cancer: some progress but a long way to go. Gastroenterology 134, 341-343, 2008.
28. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, et al.: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56, 2556-2560, 1996.